Mechanism of Action of Glucomannan as a Potential Therapeutic Agent for Type 2 Diabetes Mellitus Based on Network Pharmacology and Molecular Docking Simulation http://www.doi.org/10.26538/tjnpr/v7i12.15
Article Sidebar
Main Article Content
Abstract
Glucomannan is a polysaccharide with several health benefits such as the ability to lower blood sugar, slow gastric emptying time, accelerate satiety, and modify intestinal microbial metabolism. Therefore it has a potential as an alternative therapy for type 2 diabetes mellitus (T2DM). This study explores the mechanism of action of glucomannan as a potential therapeutic agent for T2DM through network pharmacology and molecular docking simulations.
Glucomannan and T2DM target proteins were searched using GeneCard and OpenTarget Platform, respectively. The connectivity between T2DM target proteins and glucomannan were done using Cytoscape and Venny diagrams. Virtual screening was performed using Pyrx software with protein-targeted T2DM and visualization was done using Discovery Studio. There were 9 key targets related to the mechanism of action of glucomannan based on target connectivity construction. From the docking results, the lowest binding affinity of -9.6 kcal/mol was obtained between glucomannan and 3WY1 (PDB ID of GAA/alpha-glucosidase). This binding affinity was comparable to that obtained for the positive controls; acarbose and miglitol, with binding affinity of -9.7 kcal/mol for acarbose-3WY1 complex. The 3D structure visualization showed that glucomannan and acarbose occupy the same active site on the 3WY1 structure. The results of this study indicate that the most probable mechanism of action of glucomannan is inhibition of α-glucosidase, and therefore could be a potential alternative therapeutic agent for T2DM.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Hackett RA and Steptoe A. Type 2 diabetes mellitus and psychological stress-a modifiable risk factor. Nat Rev Endocrinol. 2017;13(9):547–560.
Hui H, Tang G, Go VLW. Hypoglycemic herbs and their action mechanisms. Chin Med. 2009; 4:11.
Bibi S, Kalsoom S, Rashid H. Ligand based approach for pharmacophore generation for identification of novel compounds having antidiabetic activity. Int J Pharm Pharm Sci. 2013; 5(SUPPL.4):303–314.
Do NHN, Truong QT, Le PK, Ha AC. Recent developments in chitosan hydrogels carrying natural bioactive compounds. Carbohydr Polym. 2022; 294:119726.
Wardhani DH, Cahyono H, Dwinanda MFH, Nabila PR, Aryanti N, Pangestuti DR. Effect of KOH as Deacetylation Agent on Physicochemical Properties of Glucomannan. J Phys Conf Ser. 2019; 1295:012037.
Luo W, Liu F, Qi X, Dong G. Research progress of konjac dietary fibre in the prevention and treatment of diabetes. Food Sci Technol. 2022; 42:
Safitri AH, Widayati E, Tyagita N.Enhancing Metabolic Parameters: The Impact of Porang Glucomannan on Body Weight, Intraperitoneal Fat, Fasting Blood Glucose, and GLUT-4 Levels in Rats Fed a High-Fat and High-Carbohydrate Diet. Trop J Nat Prod Res. 2023; 7:3198–3202.
Suryana EA, Kamsiati E, Usmiati S, Herawati H. Effect of Porang Flour and Low-Calorie Sugar Concentration on the Physico-Chemical Characteristics of Jelly Drinks. IOP Conf Ser Earth Environ Sci. 2022; 985(1):1–8.
Zhao Y, Jayachandran M, Xu B. In vivo antioxidant and anti-inflammatory effects of soluble dietary fiber Konjac glucomannan in type-2 diabetic rats. Int J Biol Macromol. 2020; 159:1186–1196.
Du Q, Liu J, Ding Y. Recent progress in biological activities and health benefits of konjac glucomannan and its derivatives. Bioact Carbohydr Diet Fibre. 2021; 26:100270.
Tasakka ACMAR, Iskandar IW, Sulfahri, Suyono EA, Dewi EN, Yuwono M, et al. Molecular docking analysis of selected natural products from Halymenia sp. and Laurencia sp. seaweeds against plasmepsins as antimalarials. IOP Conf Ser Earth Environ Sci. 2022; 1119(1):012048.
Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. update. Nucleic Acids Res. 2023;51(D1):D1373–80.
Dallakyan S and Olson A. Small-molecule library screening by docking with PyRx. Methods Mol Biol. 2015; 1263:243–250.
Si Y, Liu X, Ye K, Bonfini A, Hu XY, Buchon N, et al. Glucomannan hydrolysate promotes gut proliferative homeostasis and extends life span in Drosophila melanogaster. J Gerontol - Ser A Biol Sci Med Sci. 2019; 74(10):1549–1556.
Ataie-Ashtiani S and Forbes B. A Review of the Biosynthesis and Structural Implications of Insulin Gene Mutations Linked to Human Disease. Cells. 2023; 12(7):1008.
Cerón-Rodríguez M, Castillo-García D, Acosta-Rodríguez-Bueno CP, Aguirre-Hernández J, Murillo-Eliosa JR, Valencia-Mayoral P, Sancez E, Loza S. Classic infantile-onset Pompe disease with histopathological neurologic findings linked to a novel GAA gene 4 bp deletion: A case study. Mol Genet Genomic Med. 2022; 10(7):1–9.
Gallorini M, Rapino M, Schweikl H, Cataldi A, Amoroso R, Maccallini C. Selective inhibitors of the inducible nitric oxide synthase as modulators of cell responses in LPS-stimulated human monocytes. Molecules. 2021; 26(15):4419.
Gusti AMT, Qusti SY, Bahijri SM, Toraih EA, Bokhari S, Attallah SM, Alzahrani A, Alshehri A, Alotaibi H, Fawzy M. Glutathione s-transferase (GSTT1 rs17856199) and nitric oxide synthase (nos2 rs2297518) genotype combination as potential oxidative stress-related molecular markers for type 2 diabetes mellitus. Diabet Metab Syndr Obes. 2021; 14:1385–1403.
Huang S, Qin P, Chen Q, Zhang D, Cheng C, Guo C, Li Q, Zhou Q, Tian G, Qie R, Han M, Wu X, Yang X, Feng Y, Li Y, Zhang Y, Wu Y, Liu D, Lu J, Zhang M, Zhao Y, Hu D. Association of FTO gene methylation with incident type 2 diabetes mellitus: A nested case–control study. Gene. 2021; 786:145585.
Velazquez-Roman J, Angulo-Zamudio UA, León-Sicairos N, Medina-Serrano J, DeLira-Bustillos N, Villamil-Ramírez, H, Medina-Serrano J, DeLira-Bustillos N, Villamil-Ramírez H, Canizales-Quinteros S, Macías-Kauffer L, Campos-Romero A, Alcántar-Fernández J, Canizalez-Roman A. Association of FTO, ABCA1, ADRB3, and PPARG variants with obesity, type 2 diabetes, and metabolic syndrome in a Northwest Mexican adult population. J Diabet Complic. 2021; 35(11):108025.
Sabourdy F, Labauge P, Stensland HMFR, Nieto M, Garcés VL, Renard D, Castelnovo G, de Champfleur N, Levade T. A MANBA mutation resulting in residual beta-mannosidase activity associated with severe leukoencephalopathy: A possible pseudodeficiency variant. BMC Med Genet. 2009; 10:84.
Wang L and Suzuki T. Dual functions for cytosolic α-mannosidase (Man2C1) its down-regulation causes mitochondria-dependent apoptosis independently of its α-mannosidase activity. J Biol Chem. 2013; 288(17):11887–11896.
Ding S, Xu S, Ma Y, Liu G, Jang H, Fang J. Modulatory mechanisms of the NLRP3 inflammasomes in diabetes. Biomol. 2019; 9(12):1–15.
Shin D and Lee KW. Dietary carbohydrates interacts with AMY1 polymorphisms to influence the incidence of type 2 diabetes in Korean adults. Sci Rep. 2021; 11(1):1–8.
Zia F, Zia KM, Zuber M, Ahmad HB, Muneer MI. Glucomannan based polyurethanes: A critical short review of recent advances and future perspectives. Int J Biol Macromol. 2016; 87:229-236.
Chua M, Baldwin TC, Hocking TJ, Chan K. Traditional uses and potential health benefits of Amorphophallus konjac K. Koch ex N.E.Br. J Ethnopharmacol. 2010; 128(2):268–278.
Crampon K, Giorkallos A, Deldossi M, Baud S, Steffenel LA. Machine-learning methods for ligand–protein molecular docking. Drug Discov Today. 2022; 27(1):151–164.
Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015; 20:13384–13421.
Yin B, Bi YM, Fan GJ, Xia YQ. Molecular mechanism of the effect of Huanglian Jiedu decoction on type 2 diabetes mellitus based on network pharmacology and molecular docking. J Diabet Res. 2020; 2020:5273914.
Gaillard T. Evaluation of AutoDock and AutoDock Vina on the CASF-2013 Benchmark. J Chem Inf Model. 2018; 58(8):1697–1706.
Singh G. In silico screening and pharmacokinetic properties of phytoconstituents from Ferula asafoetida H.Karst. (Heeng) as potential inhibitors of α-amylase and α-glucosidase for Type 2 Diabetes Mellitus. J Diabet Metab Disord. 2022; 21(2):1339-1347.
Ibrahim SRM, Mohamed GA, Khayat MTA, Ahmed S, Abo-Haded H. α-Amylase inhibition of xanthones from Garcinia mangostana pericarps and their possible use for the treatment of diabetes with molecular docking studies. J Food Biochem. 2019; 43(5):1–10.
Proença C, Freitas M, Ribeiro D, Oliveira EFT, Sousa JLC, Tomé SM, Ramos M, Silva A, Fernandes P, Fernandes E. α-Glucosidase inhibition by flavonoids: an in vitro and in silico structure–activity relationship study. J Enzyme Inhib Med Chem. 2017; 32(1):1216-1228.
Assefa ST, Yang E young, Chae S young, Song M, Lee J, Cho MC, Jang S. Alpha Glucosidase Inhibitory Activities of Plants with Focus on Common Vegetables. Plants (Basel). 2019; 9(1):2.
Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Stein TI, Nudel R, Lieder I, Mazor Y, Kaplan S, Dahary D, Warshawsky D, Guan-Golan Y, Kohn A, Rappaport N, Safran M, Lancet D. The GeneCards suite: From gene data mining to disease genome sequence analyses. Curr Protoc Bioinforma. 2016; 54:1.30.1-1.30.33.
Mpo CO and Summary UND. National Center for Biotechnology Information (2023) PubChem CID 24892726 Structure. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Glucomannan